CS1003

DRUG3 trials

Sponsors

Cstone Pharmaceuticals (Suzhou) Co. Ltd., CStone Pharmaceuticals

Conditions

Advanced CancerSolid Tumor, AdultUnresectable advanced hepatocellular carcinoma

Phase 1

A Study of CS1003 in Subjects With Advanced Solid Tumors

CompletedNCT03475251

CStone PharmaceuticalsAdvanced Cancer

Start: 2018-05-09End: 2021-05-31Updated: 2022-02-18

A Study of CS1002 in Subjects with Advanced Solid Tumors

CompletedNCT03523819

CStone PharmaceuticalsSolid Tumor, Adult

Start: 2018-04-26End: 2022-01-18Updated: 2024-09-19

Phase 3

A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1003 in Combination with Lenvatinib Compared to Placebo in Combination with Lenvatinib as First-Line Therapy in Subjects with Advanced Hepatocellular Carcinoma (HCC)

CompletedCTIS2024-517331-48-00

Cstone Pharmaceuticals (Suzhou) Co. Ltd.Unresectable advanced hepatocellular carcinoma

Start: 2021-01-18End: 2025-11-28Target: 74Updated: 2025-08-18

Related Papers

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma.

2024-09-042 citations

A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer.

2023-09-203 citations

Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

Cancer Research2019-07-01

Abstract 4121: Preclinical characterization of CS1003, a novel clinical-stage PD-1 monoclonal antibody

Clinical Research (Excluding Clinical Trials)2019-07-01